Trial Profile
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Infliximab (Primary) ; Mycophenolate mofetil (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MERMAID-2
- Sponsors AstraZeneca; AstraZeneca AB
- 15 Mar 2024 This trial has been completed in Denmark (Global end date: 15 Jan 2024).
- 14 Mar 2024 Status changed from active, no longer recruiting to completed.
- 08 Mar 2024 This trial has been Discontinued in Italy according to European Clinical Trials Database record.